EI
TAK icon

Ethic Inc’s Takeda Pharmaceutical TAK Stock Holding History

Ethic Inc’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.85M Buy
365,253
+30,417
+9% +$503K 0.07% 264
2026
Q1 		$6.2M Buy
334,836
+30,181
+10% +$530K 0.1% 219
2025
Q4 		$4.75M Sell
304,655
-6,096
-2% -$87.2K 0.07% 258
2025
Q3 		$4.55M Buy
310,751
+43,295
+16% +$643K 0.07% 264
2025
Q2 		$4.04M Buy
267,456
+47,921
+22% +$708K 0.07% 282
2025
Q1 		$3.27M Sell
219,535
-106,772
-33% -$1.5M 0.07% 303
2024
Q4 		$4.32M Sell
326,307
-113,512
-26% -$1.56M 0.09% 233
2024
Q3 		$6.11M Sell
439,819
-16,055
-4% -$228K 0.15% 156
2024
Q2 		$5.9M Buy
455,874
+16,055
+4% +$213K 0.14% 158
2024
Q1 		$6.11M Buy
439,819
+74,488
+20% +$1.08M 0.15% 156
2023
Q4 		$5.21M Sell
365,331
-96,516
-21% -$1.37M 0.15% 159
2023
Q3 		$7.14M Buy
461,847
+58,945
+15% +$912K 0.25% 85
2023
Q2 		$6.33M Buy
402,902
+47,123
+13% +$772K 0.23% 93
2023
Q1 		$5.86M Buy
355,779
+60,971
+21% +$971K 0.24% 96
2022
Q4 		$4.6M Buy
294,808
+155,562
+112% +$2.17M 0.25% 98
2022
Q3 		$1.81M Sell
139,246
-19,617
-12% -$273K 0.12% 211
2022
Q2 		$2.23M Sell
158,863
-87,765
-36% -$1.25M 0.16% 165
2022
Q1 		$3.53M Buy
246,628
+106,763
+76% +$1.57M 0.24% 99
2021
Q4 		$1.91M Buy
139,865
+50,384
+56% +$707K 0.15% 173
2021
Q3 		$1.47M Buy
89,481
+21,748
+32% +$365K 0.15% 176
2021
Q2 		$1.14M Buy
67,733
+10,438
+18% +$178K 0.14% 188
2021
Q1 		$1.05M Buy
57,295
+21,350
+59% +$384K 0.19% 142
2020
Q4 		$654K Buy
35,945
+315
+0.9% +$5.53K 0.17% 149
2020
Q3 		$636K Buy
35,630
+8,346
+31% +$152K 0.24% 106
2020
Q2 		$489K Buy
27,284
+5,088
+23% +$91.3K 0.28% 101
2020
Q1 		$337K Buy
22,196
+3,957
+22% +$71.7K 0.28% 123
2019
Q4 		$360K Buy
+18,239
New +$349K 0.26% 125

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Ethic Inc's TAK Position: Q2 2026 in Review

Ethic Inc increased its Takeda Pharmaceutical (TAK) stake by 9.1% in Q2 2026, buying an estimated $503K and bringing the position to 365,253 shares worth $5.85M. The position accounts for 0.07% of the portfolio, ranked #264.

Ethic Inc first reported a position in TAK in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.14M in Q3 2023. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Ethic Inc held 365,253 shares of Takeda Pharmaceutical worth $5.85M as of Q2 2026.
  • Ethic Inc bought 30,417 Takeda Pharmaceutical shares in Q2 2026, an estimated $503K.
  • Takeda Pharmaceutical made up 0.07% of Ethic Inc's portfolio in Q2 2026, its #264 holding.
  • Ethic Inc first reported a position in Takeda Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Ethic Inc's Takeda Pharmaceutical position peaked at $7.14M in Q3 2023.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.